Hongyuan Ren
A5050169570- Glycosylation and Glycoproteins Research
- Toxin Mechanisms and Immunotoxins
- Galectins and Cancer Biology
- Medicinal Plant Pharmacodynamics Research
- Polysaccharides and Plant Cell Walls
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Cancer-related gene regulation
- Energy Load and Power Forecasting
- Proteoglycans and glycosaminoglycans research
- Urinary and Genital Oncology Studies
- Wnt/β-catenin signaling in development and cancer
- Smart Grid Energy Management
- Electric Vehicles and Infrastructure
- Integrated Energy Systems Optimization
- Thermodynamic and Exergetic Analyses of Power and Cooling Systems
- Technology and Security Systems
- Power Systems and Technologies
- Smart Grid Security and Resilience
- Refrigeration and Air Conditioning Technologies
Bioscience (China)
2023
Abstract Overexpression of nectin cell adhesion protein 4 correlates with cancer progression and poor prognosis in many human malignancies. Enfortumab vedotin (EV) is the first nectin-4–targeting antibody–drug conjugate (ADC) approved by FDA for treatment urothelial cancer. However, inadequate efficacy has limited progress other solid tumors EV. Furthermore, ocular, pulmonary, hematologic toxic side effects are common nectin-4–targeted therapy, which frequently results dose reduction and/or...
Abstract Multi-station integration is a new form of business in the development energy Internet and brand practice power iot. It an innovative that strengthens interaction between charge storage source network on both sides supply demand, enhances flexibility grid by taking substation, station, distributed station other resources as core. However, there not set construction mode can guide implementation, copy popularize. Therefore, guided existing multi-station fusion China combined with...
<p>Comparison of the structure 9MW2821 and enfortumab vedotin.</p>
<p>Binding specificity based on enzyme-linked immunosorbent assay.</p>
<p>Binding affinity measured by Biolayer interferometry.</p>
<div>Abstract<p>Overexpression of nectin cell adhesion protein 4 correlates with cancer progression and poor prognosis in many human malignancies. Enfortumab vedotin (EV) is the first nectin-4-targeting antibody drug conjugate approved by US Food Drug Administration for treatment urothelial cancer. However, inadequate efficacy has limited progress other solid tumors EV. Furthermore, ocular, pulmonary, hematological toxic side effects are common nectin-4-targeted therapy, which...
<p>Binding affinity based on enzyme-linked immunosorbent assay.</p>
<p>Mouse body weight from BL3578, CV13641, LU3073, BR9457, BR9479, BR1282 and BR1458 patient-derived xenograft studies.</p>
<p>Cynomolgus monkey body weight in safety evaluation study</p>
<p>The nectin-4 expression for BR1282</p>
<p>Affinity of 9MW2821 and enfortumab vedotin (EV) to recombinant human Fcγ FcRn receptors based on surface plasmon resonance measurements.</p>
<p>Mouse body weight from MDA-MB-468, NCI-H322 and HT1376 cell-derived xenograft studies.</p>
<p>Characterization of 9MW2821.</p>